No House member has disclosed a PBLS trade since 2025.
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 21, 2026 | Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 27.13 - 30.00 per share. | 244.6K | $6.92M |
| Jun 14, 2026 | Sebulsky Alan MDirector | Purchase at price 26.00 - 27.67 per share. | 17.5K | $473.53K |
| Jun 10, 2026 | Sebulsky Alan MDirector | Purchase at price 30.31 per share. | 12.5K | $378.88K |
| Jun 10, 2026 | Flynn James EBeneficial Owner of more than 10% of a Class of Security | — | 1.88M | — |
| Jun 10, 2026 | Fitzgerald Edward MDirector | — | 14.7K | — |
| Jun 10, 2026 | Borisy AlexisDirector | — | 105.4K | — |
| Jun 10, 2026 | Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 30.31 per share. | 21.19M | $642.23M |
| Jun 10, 2026 | Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security | — | 7.74M | — |
| Jun 10, 2026 | Levy Guy BBeneficial Owner of more than 10% of a Class of Security | Purchase at price 30.31 per share. | 500K | $15.15M |
| Jun 10, 2026 | Levy Guy BBeneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 9.48 per share. | 527.1K | $5.00M |
Buy / hold / sell counts
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.